Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000218410 encodes a **pseudogene** related to the *envelope (env)* protein of the human endogenous retrovirus family FRD, specifically analogous to the ancestral envelope proteins found in Old World monkeys and other primates[1][2]. In Old World monkeys, the functional ortholog of this gene (sometimes called syncytin) mediates the fusion of placental cells (syncytiotrophoblast formation) critical for placental development[2]. In humans, however, this locus is interrupted by frameshifts and stop codons and does **not** encode a functional protein—it is a genetically inactive remnant (“pseudogene”)[2]. There is no evidence that the human pseudogene has an active role in cellular physiology, disease, or as a therapeutic target[1][2]. Other **human endogenous retroviral envelope genes** that remain functional (e.g., ERVW-1/SYNCYTIN-1, ERVFRD-1/SYNCYTIN-2) have important roles in placentation, but ENSG00000218410 does **not** contribute to this process[2]. There is no evidence this locus is targeted by drugs or is used as a clinical biomarker. **Key points:** - ENSG00000218410 is a retained sequence of an ancient viral gene but **not** a functional gene in humans[1]. - Its orthologs (not the human version) in Old World monkeys mediate cell fusion in placenta[2]. - It is **not a receptor, enzyme, transporter, transcription factor, or any canonical drug target protein**[1][2]. - It does **not** have established diagnostic, therapeutic, or pathological significance in modern humans[1]. This pseudogene represents the remnants of a viral gene that contributed to mammalian evolution but is no longer functional or clinically relevant in humans.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pseudogene similar to primate FRD envelope proteins.